Pivotal Therapeutics Inc.
CNSX : PVO

Pivotal Therapeutics Inc.

September 08, 2011 12:52 ET

Pivotal Therapeutics Inc. Presents at BIOFLORIDA Conference

WOODBRIDGE, ONTARIO--(Marketwire - Sept. 8, 2011) - Pivotal Therapeutics Inc. (CNSX:PVO) a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease, today reported that Dr. George Jackowski, Chairman and Chief Scientific Officer presented highlights of the Company and its research on August 31, 2011 at the BIOFLORIDA Southeast Chapter Event. The presentation was given at the Research Park at Florida Atlantic University (FAU) in Boca Raton, Florida.

"It was an honour to present at the BIOFLORIDA event at the Research Park especially given that Pivotal's regional product commercialization and distribution will be centered in Boca Raton." said Dr. Jackowski. "We are very proud to have been accepted into the Florida community where we will be launching our lead therapeutic, VASCAZEN™, in Orlando, Florida at the American Heart Association's (AHA) Scientific Sessions 2011 this November."

In June 2011, Pivotal announced the opening of its US Headquarters at the Research Park at FAU. The Florida Atlantic Research Park is Florida's top destination for technology companies to thrive collaborating with the region's premier research university. Located adjacent to the main campus of FAU, the Park is in close proximity to Scripps Florida, Torrey Pines Institute for Molecular Studies, the University of Miami Miller School of Medicine, the world-renowned Harbor Branch Research Centre.

"Given the exciting developments at the Company as we move towards VASCAZEN's™ North American product launch this fall, it is our intent to keep the research and investment communities apprised of Pivotal's progress," says Eugene Bortoluzzi, Chief Executive Officer and Chief Financial Officer. "As part of those plans Pivotal will also be presenting at the prestigious Rodman & Renshaw Annual Global Investment Conference on September 13th in New York."

The Canadian launch of VASCAZEN™ at the Canadian Cardiovascular Congress Vancouver 2011, hosted by the Canadian Cardiovascular Society & the Heart and Stroke Foundation of Canada, will take place from October 22 - 26 at the Vancouver Convention Centre in Vancouver, Canada.

The American launch of VASCAZEN™ at the AHA's Scientific Sessions 2011 will take place from November 13-15, 2011 at the Orange County Convention Centre in Orlando, Florida. Both conferences represent the largest and most prestigious gathering of physicians, scientist and healthcare professionals.

About BIOFLORIDA (www.bioflorida.com)

BIOFLORIDA is the voice of Florida's bioscience industry representing more than 3,000 companies and research organizations in the biotechnology, pharmaceutical and medical device fields employing 61,000 Floridians. BIOFLORIDA's member-driven initiatives provide a strong business climate for production of quality, life-improving technologies and promote economic benefits to the state. BIOFLORIDA influences the growth of the industry through exceptional programming that offers networking and business development opportunities, access to capital, and information regarding public policy efforts.

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (CNSX:PVO) specialty pharmaceutical company with a focus on the treatment of cardiovascular disease. Pivotal Therapeutics' lead product VASCAZEN™ is a prescription medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with reduced risk of cardiovascular complications.

VASCAZEN™ is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected by a series of both issued and pending US and foreign patents and commercialized by prescription only. This unique formulation will provide the cornerstone upon which a family of cutting edge combination products, with efficacy across a broad spectrum of cardiac care, will be commercialized.

Disclosure Notice

The information contained in this document is as of September 8, 2011. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CNSX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments.

Contact Information